Company intelligence / Profile preview

Accent Therapeutics

Lexington, Massachusetts, United Statesaccenttx.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Accent Therapeutics has two clinical-stage programs: ATX-559 (DHX9 inhibitor) and ATX-295 (KIF18A inhibitor). The first patient was dosed in the Phase 1/2 trial for ATX-295 in April 2025, and both lead assets have received FDA Fast Track designation. ATX-559 is being evaluated in patients with BRCA1/2-deficient breast cancer and MSI-H/dMMR solid tumors, while ATX-295 is being tested in patients with advanced solid tumors including ovarian cancer.

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

7 assets

ATX-295

6 more assets in the full pipeline.

Beyond the preview

Go deeper on Accent Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Accent Therapeutics.